Ovid Capital Expenditures vs Depreciation Analysis

OVID Stock

USD 1.06 0.01 0.95%

Ovid Therapeutics financial indicator trend analysis is much more than just breaking down Ovid Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ovid Therapeutics is a good investment. Please check the relationship between Ovid Therapeutics Capital Expenditures and its Depreciation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.

Capital Expenditures vs Depreciation

Capital Expenditures vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ovid Therapeutics Capital Expenditures account and Depreciation. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Ovid Therapeutics' Capital Expenditures and Depreciation is 0.48. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Depreciation in the same time period over historical financial statements of Ovid Therapeutics, assuming nothing else is changed. The correlation between historical values of Ovid Therapeutics' Capital Expenditures and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Ovid Therapeutics are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Capital Expenditures i.e., Ovid Therapeutics' Capital Expenditures and Depreciation go up and down completely randomly.

Correlation Coefficient

0.48

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Ovid Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Ovid Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Depreciation

Depreciation indicates how much of Ovid Therapeutics value has been used up. For tax purposes Ovid Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Ovid Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Ovid Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ovid Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.At present, Ovid Therapeutics' Sales General And Administrative To Revenue is projected to increase significantly based on the last few years of reporting.

	2023	2024 (projected)
Depreciation And Amortization	1.6M	1.7M
Interest Income	5.6M	5.9M

Depreciation And Amortization Interest Income

Ovid Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Preferred Stock Total Equity
Total Assets		0.67	0.97	0.99	-0.74	0.77	0.83	0.46	0.9	0.6	0.99	0.56	0.82	0.62	0.54	0.55	-0.37	0.56	0.68	0.82	0.33	0.87	0.77	0.87	0.56	-0.76
Total Current Liabilities	0.67		0.57	0.58	-0.88	0.93	0.54	0.29	0.8	0.63	0.69	0.78	0.81	0.34	0.98	0.23	-0.11	0.3	0.54	0.41	0.39	0.83	0.83	0.86	0.24	-0.82
Total Stockholder Equity	0.97	0.57		0.96	-0.61	0.71	0.9	0.53	0.81	0.45	0.99	0.52	0.72	0.51	0.43	0.45	-0.49	0.45	0.63	0.85	0.33	0.76	0.65	0.77	0.45	-0.7
Net Tangible Assets	0.99	0.58	0.96		-0.67	0.7	0.78	0.43	0.86	0.57	0.96	0.48	0.77	0.62	0.44	0.55	-0.34	0.57	0.66	0.82	0.3	0.83	0.74	0.82	0.56	-0.7
Retained Earnings	-0.74	-0.88	-0.61	-0.67		-0.79	-0.41	-0.27	-0.88	-0.85	-0.7	-0.81	-0.88	-0.69	-0.86	-0.62	-0.14	-0.66	-0.66	-0.41	-0.5	-0.92	-0.92	-0.94	-0.62	0.9
Accounts Payable	0.77	0.93	0.71	0.7	-0.79		0.66	0.48	0.79	0.55	0.79	0.77	0.78	0.31	0.85	0.19	-0.28	0.28	0.67	0.59	0.42	0.81	0.85	0.84	0.19	-0.83
Cash	0.83	0.54	0.9	0.78	-0.41	0.66		0.59	0.66	0.13	0.88	0.42	0.57	0.17	0.42	0.12	-0.76	0.08	0.48	0.77	0.15	0.58	0.45	0.61	0.12	-0.54
Other Assets	0.46	0.29	0.53	0.43	-0.27	0.48	0.59		0.35	-0.05	0.48	0.57	0.28	0.06	0.16	0.06	-0.4	0.03	0.8	0.32	0.36	0.3	0.47	0.38	0.06	-0.51
Common Stock Shares Outstanding	0.9	0.8	0.81	0.86	-0.88	0.79	0.66	0.35		0.74	0.87	0.64	0.96	0.7	0.73	0.64	-0.21	0.64	0.67	0.71	0.26	0.98	0.87	0.97	0.64	-0.79
Total Liab	0.6	0.63	0.45	0.57	-0.85	0.55	0.13	-0.05	0.74		0.53	0.44	0.71	0.89	0.61	0.81	0.36	0.9	0.52	0.36	0.21	0.75	0.76	0.75	0.82	-0.66
Total Current Assets	0.99	0.69	0.99	0.96	-0.7	0.79	0.88	0.48	0.87	0.53		0.58	0.78	0.53	0.56	0.46	-0.44	0.47	0.64	0.83	0.34	0.83	0.73	0.84	0.46	-0.75
Intangible Assets	0.56	0.78	0.52	0.48	-0.81	0.77	0.42	0.57	0.64	0.44	0.58		0.67	0.29	0.75	0.23	0.06	0.27	0.67	0.22	0.77	0.7	0.78	0.76	0.23	-0.85
Common Stock	0.82	0.81	0.72	0.77	-0.88	0.78	0.57	0.28	0.96	0.71	0.78	0.67		0.64	0.77	0.58	-0.21	0.58	0.58	0.7	0.34	0.98	0.85	0.97	0.59	-0.79
Property Plant Equipment	0.62	0.34	0.51	0.62	-0.69	0.31	0.17	0.06	0.7	0.89	0.53	0.29	0.64		0.29	0.99	0.26	0.99	0.55	0.46	0.12	0.67	0.63	0.67	0.99	-0.54
Other Current Liab	0.54	0.98	0.43	0.44	-0.86	0.85	0.42	0.16	0.73	0.61	0.56	0.75	0.77	0.29		0.19	-0.04	0.25	0.41	0.3	0.36	0.77	0.75	0.8	0.19	-0.75
Property Plant And Equipment Net	0.55	0.23	0.45	0.55	-0.62	0.19	0.12	0.06	0.64	0.81	0.46	0.23	0.58	0.99	0.19		0.27	0.97	0.5	0.4	0.09	0.6	0.55	0.6	1.0	-0.47
Net Debt	-0.37	-0.11	-0.49	-0.34	-0.14	-0.28	-0.76	-0.4	-0.21	0.36	-0.44	0.06	-0.21	0.26	-0.04	0.27		0.35	-0.05	-0.67	0.2	-0.14	0.04	-0.14	0.27	0.03
Non Current Assets Total	0.56	0.3	0.45	0.57	-0.66	0.28	0.08	0.03	0.64	0.9	0.47	0.27	0.58	0.99	0.25	0.97	0.35		0.55	0.4	0.13	0.62	0.62	0.62	0.97	-0.52
Non Currrent Assets Other	0.68	0.54	0.63	0.66	-0.66	0.67	0.48	0.8	0.67	0.52	0.64	0.67	0.58	0.55	0.41	0.5	-0.05	0.55		0.41	0.39	0.64	0.84	0.7	0.51	-0.77
Cash And Short Term Investments	0.82	0.41	0.85	0.82	-0.41	0.59	0.77	0.32	0.71	0.36	0.83	0.22	0.7	0.46	0.3	0.4	-0.67	0.4	0.41		0.07	0.66	0.48	0.65	0.41	-0.47
Net Receivables	0.33	0.39	0.33	0.3	-0.5	0.42	0.15	0.36	0.26	0.21	0.34	0.77	0.34	0.12	0.36	0.09	0.2	0.13	0.39	0.07		0.38	0.5	0.45	0.09	-0.69
Common Stock Total Equity	0.87	0.83	0.76	0.83	-0.92	0.81	0.58	0.3	0.98	0.75	0.83	0.7	0.98	0.67	0.77	0.6	-0.14	0.62	0.64	0.66	0.38		0.89	0.99	0.61	-0.83
Other Current Assets	0.77	0.83	0.65	0.74	-0.92	0.85	0.45	0.47	0.87	0.76	0.73	0.78	0.85	0.63	0.75	0.55	0.04	0.62	0.84	0.48	0.5	0.89		0.92	0.56	-0.92
Other Stockholder Equity	0.87	0.86	0.77	0.82	-0.94	0.84	0.61	0.38	0.97	0.75	0.84	0.76	0.97	0.67	0.8	0.6	-0.14	0.62	0.7	0.65	0.45	0.99	0.92		0.6	-0.9
Property Plant And Equipment Gross	0.56	0.24	0.45	0.56	-0.62	0.19	0.12	0.06	0.64	0.82	0.46	0.23	0.59	0.99	0.19	1.0	0.27	0.97	0.51	0.41	0.09	0.61	0.56	0.6		-0.48
Preferred Stock Total Equity	-0.76	-0.82	-0.7	-0.7	0.9	-0.83	-0.54	-0.51	-0.79	-0.66	-0.75	-0.85	-0.79	-0.54	-0.75	-0.47	0.03	-0.52	-0.77	-0.47	-0.69	-0.83	-0.92	-0.9	-0.48

Click cells to compare fundamentals

Ovid Therapeutics Account Relationship Matchups

Ovid Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	80.8M	75.9M	194.5M	155.3M	144.0M	100.8M
Total Current Liabilities	10.5M	22.1M	14.8M	7.0M	11.5M	9.6M
Total Stockholder Equity	70.0M	43.6M	179.7M	132.3M	87.8M	83.4M
Net Tangible Assets	69.6M	43.3M	179.7M	132.3M	152.1M	81.7M
Retained Earnings	(213.2M)	(294.2M)	(171.4M)	(225.5M)	(277.9M)	(264.0M)
Accounts Payable	3.3M	5.4M	7.1M	2.0M	3.7M	3.2M
Cash	41.9M	72.0M	187.8M	129.0M	27.0M	25.7M
Other Assets	494.9K	(100.0)	2.0M	1.9M	1.0	0.95
Common Stock Shares Outstanding	39.2M	58.5M	68.1M	70.4M	70.6M	44.0M
Total Liab	10.8M	32.3M	14.8M	23.0M	56.2M	59.0M
Total Current Assets	79.8M	74.8M	190.5M	131.4M	109.6M	93.1M
Intangible Assets	467.2K	318.9K	260.1K	261.2K	183.0K	235.2K
Common Stock	54.7K	65.7K	70.4K	70.5K	70.7K	47.4K
Property Plant Equipment	68.4K	135.6K	242.8K	1.1M	1.3M	1.4M
Other Current Liab	7.3M	14.4M	7.7M	4.5M	6.5M	6.6M
Property Plant And Equipment Net	68.4K	135.6K	242.8K	16.1M	14.7M	15.4M
Net Debt	(41.9M)	(72.0M)	(187.8M)	(112.5M)	(11.0M)	(11.6M)
Non Current Assets Total	1.0M	1.1M	4.1M	23.9M	34.4M	36.2M
Non Currrent Assets Other	495.2K	627.8K	1.9M	2.0M	2.0M	1.4M
Cash And Short Term Investments	76.7M	72.0M	187.8M	129.0M	105.8M	100.5M
Common Stock Total Equity	54.7K	65.7K	70.4K	70.5K	81.0K	46.7K
Liabilities And Stockholders Equity	80.8M	75.9M	194.5M	155.3M	144.0M	111.4M
Other Current Assets	1.9M	2.7M	2.7M	2.4M	3.8M	2.2M
Other Stockholder Equity	283.1M	337.8M	351.0M	357.8M	365.6M	276.7M
Property Plant And Equipment Gross	68.4K	135.6K	505.0K	16.7M	15.7M	16.4M
Accumulated Other Comprehensive Income	(50.9K)	(1.8K)	2.5K	(42.2K)	702.0	737.1
Non Current Liabilities Total	286.6K	10.2M	7.1M	16.0M	44.8M	47.0M
Retained Earnings Total Equity	(213.2M)	(294.2M)	(171.4M)	(225.5M)	(203.0M)	(213.1M)
Capital Surpluse	283.1M	337.8M	351.0M	357.8M	411.4M	312.6M
Net Invested Capital	70.0M	43.6M	179.7M	132.3M	87.8M	99.9M
Net Working Capital	69.3M	52.8M	175.7M	124.4M	98.1M	100.3M
Capital Stock	54.7K	65.7K	70.4K	70.5K	70.7K	65.4K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:

How To Invest In Ovid

Details

Is Ovid Stock a good investment?

Details

What is Ovid Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.46)

Revenue Per Share

0.009

Quarterly Revenue Growth

0.587

Return On Assets

(0.36)

Return On Equity

(0.37)

The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ovid Capital Expenditures vs Depreciation Analysis

Capital Expenditures vs Depreciation

Capital Expenditures vs Depreciation Correlation Analysis

Correlation Coefficient

Capital Expenditures

Depreciation

Ovid Therapeutics fundamental ratios Correlations

Ovid Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ovid Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Net Tangible Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity
Property Plant And Equipment Net	+ 0.99	Property Plant Equipment
Non Current Assets Total	+ 0.99	Property Plant Equipment

Other Stockholder Equity	- 0.94	Retained Earnings
Preferred Stock Total Equity	- 0.92	Other Current Assets
Other Current Assets	- 0.92	Retained Earnings
Common Stock Total Equity	- 0.92	Retained Earnings
Preferred Stock Total Equity	- 0.9	Other Stockholder Equity
Common Stock	- 0.88	Retained Earnings